MX2023000868A - Derivado de isoindolina que contiene azufre, metodo de preparacion y uso medico del mismo. - Google Patents
Derivado de isoindolina que contiene azufre, metodo de preparacion y uso medico del mismo.Info
- Publication number
- MX2023000868A MX2023000868A MX2023000868A MX2023000868A MX2023000868A MX 2023000868 A MX2023000868 A MX 2023000868A MX 2023000868 A MX2023000868 A MX 2023000868A MX 2023000868 A MX2023000868 A MX 2023000868A MX 2023000868 A MX2023000868 A MX 2023000868A
- Authority
- MX
- Mexico
- Prior art keywords
- sulfur
- preparation
- method therefor
- medical use
- isoindoline derivative
- Prior art date
Links
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 title abstract 3
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical class C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 title abstract 3
- 238000002360 preparation method Methods 0.000 title abstract 3
- 229910052717 sulfur Inorganic materials 0.000 title abstract 3
- 239000011593 sulfur Substances 0.000 title abstract 3
- 101000941994 Homo sapiens Protein cereblon Proteins 0.000 abstract 1
- 208000034578 Multiple myelomas Diseases 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 102100032783 Protein cereblon Human genes 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/54—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
La presente invención se refiere a un derivado de isoindolina que contiene azufre ya un método de preparación del mismo y a su uso médico. En particular, la presente invención se refiere a un derivado de isoindolina que contiene azufre representado por la Formula general (I), un método de preparación del mismo, una composición farmacéutica que contiene el derivado y su uso como agente terapéutico, en particular su uso como modulador de Cereblon. en el campo del tratamiento del mieloma múltiple. (ver Fórmula).
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010696995 | 2020-07-20 | ||
CN202010783483 | 2020-08-06 | ||
CN202011223930 | 2020-11-05 | ||
CN202110410441 | 2021-04-16 | ||
PCT/CN2021/107297 WO2022017365A1 (zh) | 2020-07-20 | 2021-07-20 | 含硫异吲哚啉类衍生物、其制备方法及其在医药上的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023000868A true MX2023000868A (es) | 2023-02-22 |
Family
ID=79728998
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023000868A MX2023000868A (es) | 2020-07-20 | 2021-07-20 | Derivado de isoindolina que contiene azufre, metodo de preparacion y uso medico del mismo. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230257366A1 (es) |
EP (1) | EP4183781A4 (es) |
JP (1) | JP2023534528A (es) |
KR (1) | KR20230042057A (es) |
CN (1) | CN115916768A (es) |
AU (1) | AU2021314401A1 (es) |
BR (1) | BR112023000817A2 (es) |
CA (1) | CA3184711A1 (es) |
MX (1) | MX2023000868A (es) |
TW (1) | TW202214594A (es) |
WO (1) | WO2022017365A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023138647A1 (zh) * | 2022-01-19 | 2023-07-27 | 江苏恒瑞医药股份有限公司 | 一种含硫异吲哚啉类衍生物的晶型 |
US20240158370A1 (en) | 2022-09-09 | 2024-05-16 | Innovo Therapeutics, Inc. | CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050143344A1 (en) | 2003-12-30 | 2005-06-30 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
ZA200704890B (en) | 2004-11-23 | 2008-09-25 | Celgene Corp | Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury |
MY180812A (en) | 2007-03-20 | 2020-12-09 | Celgene Corp | 4'-o-substituted isoindoline derivattives and compositions comprising and methods of using the same |
JP2013519675A (ja) | 2010-02-11 | 2013-05-30 | セルジーン コーポレイション | アリールメトキシイソインドリン誘導体、それを含む組成物、及びその使用方法 |
UA123786C2 (uk) * | 2016-04-06 | 2021-06-02 | Дзе Ріджентс Оф Дзе Юніверсіті Оф Мічіган | Деструктори білка mdm2 |
EP3381474A1 (en) * | 2017-03-27 | 2018-10-03 | Alfasigma S.p.A. | Histone deacetylase inhibitors-based antibody drug conjugates (adcs) and use in therapy |
KR102656934B1 (ko) * | 2017-07-10 | 2024-04-16 | 셀진 코포레이션 | 항증식성 화합물 및 이의 사용 방법 |
US10513515B2 (en) | 2017-08-25 | 2019-12-24 | Biotheryx, Inc. | Ether compounds and uses thereof |
CN112492874A (zh) * | 2018-05-23 | 2021-03-12 | 细胞基因公司 | 治疗多发性骨髓瘤以及生物标志物对于4-(4-(4-(((2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-4-基)氧基)甲基)苄基)哌嗪-1-基)-3-氟苄腈的用途 |
JP7168773B2 (ja) | 2018-09-30 | 2022-11-09 | 上海 インスティテュート オブ マテリア メディカ、チャイニーズ アカデミー オブ サイエンシーズ | イソインドリン化合物、その調製方法、医薬組成物および使用 |
WO2021055756A1 (en) * | 2019-09-19 | 2021-03-25 | The Regents Of The University Of Michigan | Spirocyclic androgen receptor protein degraders |
-
2021
- 2021-07-20 US US18/017,388 patent/US20230257366A1/en active Pending
- 2021-07-20 JP JP2023503463A patent/JP2023534528A/ja active Pending
- 2021-07-20 TW TW110126626A patent/TW202214594A/zh unknown
- 2021-07-20 EP EP21847148.0A patent/EP4183781A4/en active Pending
- 2021-07-20 WO PCT/CN2021/107297 patent/WO2022017365A1/zh active Application Filing
- 2021-07-20 BR BR112023000817A patent/BR112023000817A2/pt unknown
- 2021-07-20 CA CA3184711A patent/CA3184711A1/en active Pending
- 2021-07-20 KR KR1020237005618A patent/KR20230042057A/ko unknown
- 2021-07-20 AU AU2021314401A patent/AU2021314401A1/en active Pending
- 2021-07-20 MX MX2023000868A patent/MX2023000868A/es unknown
- 2021-07-20 CN CN202180041057.4A patent/CN115916768A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
BR112023000817A2 (pt) | 2023-02-07 |
TW202214594A (zh) | 2022-04-16 |
CA3184711A1 (en) | 2022-01-27 |
AU2021314401A1 (en) | 2023-03-09 |
CN115916768A (zh) | 2023-04-04 |
US20230257366A1 (en) | 2023-08-17 |
WO2022017365A1 (zh) | 2022-01-27 |
EP4183781A4 (en) | 2024-01-03 |
EP4183781A1 (en) | 2023-05-24 |
KR20230042057A (ko) | 2023-03-27 |
JP2023534528A (ja) | 2023-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021006421A (es) | Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17). | |
MX2021007970A (es) | Derivado de 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y uso medico del mismo. | |
CR20220363A (es) | Compuestos tricíclicos sustituidos | |
WO2019199861A3 (en) | Hemp extract for treatment of pain in animals | |
MX2023000868A (es) | Derivado de isoindolina que contiene azufre, metodo de preparacion y uso medico del mismo. | |
MX2009008228A (es) | N-adamantil benzamidas como inhibidores de la dehidrogenasa 11-beta-hidroxiesteroide. | |
PH12015501740A1 (en) | Sodium channel modulators for the treatment of pain | |
MX368504B (es) | Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos. | |
EA201071040A1 (ru) | Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1, cx3cr1 и p40 | |
SG10201805552PA (en) | Sodium channel modulators for the treatment of pain and diabetes | |
EP4327886A3 (en) | Pyrimido- pyridazinone compounds and use thereof | |
MX2021011823A (es) | Derivado pirroloheterociclico, metodo de preparacion del mismo y su aplicacion en medicina. | |
MX2023007853A (es) | Compuesto heterociclico puenteado que contiene nitrogeno, metodo de preparacion y uso medico del mismo. | |
MX2011009709A (es) | Compuestos para el tratamiento de la inflamacion y del dolor. | |
MX2023005533A (es) | Derivado de triazina diona, metodo de preparacion y aplicacion del mismo en medicina. | |
MX2022015531A (es) | Derivado de piridina-pirimidina, metodo de preparacion y uso farmaceutico del mismo. | |
MX2019010695A (es) | Compuesto antimicrobiano ((2r,3s,5r)-5-(4-amino-2-oxopirimidin-1(2 h)- il)-3-((butoxióxidofosfor-il)oxi) tetrahidrofuran-2-il)metil butil fosfato, y el uso del mismo en infecciones. | |
MX2022015554A (es) | Moduladores de molecula peque?a de interleucina 17 (il-17). | |
MX2023006504A (es) | Compuesto de hidroxamato, metodo de preparacion del mismo y aplicacion del mismo. | |
WO2009019708A3 (en) | Pharmaceutical compositions and methods for the treatment of cancer | |
CR20220538A (es) | Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso | |
MX339096B (es) | Compuestos inhibidores de metaloproteasa a base de feniletiniltiofeno y su uso en el tratamiento del dolor y otras enfermedades. | |
MX2023011166A (es) | Compuesto de tetrahidronaftaleno, metodo de preparacion y uso del mismo en medicina. | |
MX2021009170A (es) | Cristal de compuesto de diariltiohidantoina. | |
WO2023137403A3 (en) | Compound comprising raltitrexed or 5-mthf linked to a therapeutic agent, composition, and method of use |